Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
US11447545B2 · kind B2 · utility
0Cited by
1References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 9, 2018 |
| Grant date | Sep 20, 2022 |
| Priority date | — |
| Expiry date | Mar 12, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.